Cowen and Company Reiterates “Outperform” Rating for Cepheid (CPHD)
Cepheid (NASDAQ:CPHD)‘s stock had its “outperform” rating reiterated by research analysts at Cowen and Company in a report released on Thursday. They currently have a $58.00 price objective on the stock, down from their previous price objective of $62.00. Cowen and Company’s price objective would indicate a potential upside of 21.34% from the stock’s previous close.
Cepheid (NASDAQ:CPHD) traded up 0.10% during mid-day trading on Thursday, hitting $47.798. The stock had a trading volume of 297,519 shares. Cepheid has a 52-week low of $30.95 and a 52-week high of $55.89. The stock has a 50-day moving average of $46.40 and a 200-day moving average of $48.00. The company’s market cap is $3.333 billion.
Cepheid (NASDAQ:CPHD) last released its earnings data on Thursday, April 17th. The company reported ($0.01) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.17) by $0.16. The company had revenue of $106.90 million for the quarter, compared to the consensus estimate of $104.90 million. During the same quarter last year, the company posted $0.11 earnings per share. Cepheid’s revenue was up 16.3% compared to the same quarter last year. On average, analysts predict that Cepheid will post $-0.35 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Wells Fargo & Co. initiated coverage on shares of Cepheid in a research note on Wednesday. They set an “outperform” rating on the stock. Separately, analysts at Craig Hallum upgraded shares of Cepheid from a “sell” rating to a “hold” rating in a research note on Monday, June 9th. Finally, analysts at SunTrust reiterated a “neutral” rating on shares of Cepheid in a research note on Monday, June 9th. They now have a $49.00 price target on the stock, down previously from $54.00. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $51.71.
In other Cepheid news, EVP Kerry Flom sold 1,282 shares of the stock on the open market in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $48.97, for a total transaction of $62,779.54. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.